|
|||||
|
|
| 乳腺癌Her2基因荧光原位杂交及其临床病理关系 | |
| 引用本文： | 杜江,刘小超,康文婷,周全,尹鸿雁,刘红刚. 乳腺癌Her2基因荧光原位杂交及其临床病理关系[J]. 临床与实验病理学杂志, 2010, 26(1) |
| 作者姓名： | 杜江 刘小超 康文婷 周全 尹鸿雁 刘红刚 |
| 作者单位： | 首都医科大学附属北京同仁医院病理科,北京,100730 |
| 基金项目： | 卫生部科研基金(NoWKJ2007-3-001) |
| 摘 要： | 目的探讨Her2基因过表达的比例及其与临床病理之间的联系。方法收集乳腺浸润型导管癌标本50例,总结其临床及病理资料,应用石蜡包埋组织切片,以EnVision两步法进行免疫组织化学染色标记ER、PR及HER2,以金菩嘉DNA探针试剂盒行荧光原位杂交检测HER2基因。结果患者平均年龄55.5岁,病理组织分级Ⅰ级11例,Ⅱ级30例,Ⅲ级9例。术后分期Ⅰ期13例,ⅡA期15例,ⅡB期13例,ⅢA期6例,ⅢB期2例,ⅢC期1例。淋巴结中位转移率6.91%。ER阳性33例,PR阳性32例,IHC法HER2阳性40例,FISH阳性33例,阴性17例。FISH法检测HER2基因与HER2蛋白过表达之间相关(P0.05),其与病理分级、术后分期、淋巴结转移率及ER、PR的表达无相关(P0.05),3例脉管内瘤栓及3例原发瘤数大于1者,FISH均为阳性。结论FISH检测HER2基因扩增和免疫组化检测HER2蛋白一致性较好,HER2基因与脉管内瘤栓及多个原发瘤有一定关系,但其作为间接预测预后的指标有待于进一步研究。 |
| 关 键 词： | 乳腺浸润性导管癌 基因 HER2 原位杂交 荧光 免疫组织化学 |
HER2 gene amplification in breast cancer by fluorescence in-situ hybridization and its clinicopathologic relationship |
|
| DU Jiang,LIU Xiao-chao,KANG Wen-ting,ZHOU Quan,YIN Hong-yan,LIU Hong-gang. HER2 gene amplification in breast cancer by fluorescence in-situ hybridization and its clinicopathologic relationship[J]. Chinese Journal of Clinical and Experimental Pathology, 2010, 26(1) | |
| Authors: | DU Jiang LIU Xiao-chao KANG Wen-ting ZHOU Quan YIN Hong-yan LIU Hong-gang |
| Affiliation: | Department of Pathology/a>;Beijing Toren Hospital/a>;Capital Medical University/a>;Beijing 100730/a>;China |
| Abstract: | Purpose To detect the HER2 gene amplification by fluorescence in-situ hybridization(FISH) and to explore its clinicopathologic relationship with the breast cancer.Methods A prospective study was conducted in 50 cases of breast invasive ductal carcinoma from Beijing Toren Hospital.Clinicopathologic data were summarized and FISH was performed in the paraffin-embedded sections for HER2 gene amplificayion using DNA probe,and immunohistochemical stain for ER,PR and HER2.Results The average age of the patients wa... |
| Keywords: | breast invasive ductal carcinoma genes HER2 insitu hybridization fluorescence immunohistochemistry |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |